Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total product sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q2 2026
7,627
Period ended Jun 30, 2026
Change on a year earlier
+8.1%
7,054 in Q2 2025
History
37 quarters
Since Q2 2017
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 7,627 | +8.1% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 6,946 | +5.0% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 7,902 | +4.9% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 7,345 | -2.3% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 7,054 | +2.1% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 6,613 | -0.5% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 7,536 | +6.6% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 7,515 | +7.4% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 6,912 | +5.3% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 6,647 | +5.4% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 7,070 | -3.6% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 6,994 | +0.2% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 6,564 | +6.9% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 6,306 | -3.5% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 7,332 | +2.4% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 6,978 | -5.1% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 6,138 | -0.2% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 6,534 | +3.1% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 7,160 | -2.3% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 7,356 | +13.3% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 6,152 | +21.4% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 6,340 | +16.0% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 7,328 | +26.4% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 6,493 | +17.7% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 5,067 | -9.6% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 5,467 | +5.1% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 5,796 | +2.0% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 5,516 | +1.1% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 5,607 | +1.2% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 5,200 | +4.0% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 5,681 | -2.7% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 5,455 | -14.8% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 5,540 | -21.4% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 5,001 | – | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 5,837 | – | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 6,402 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 7,046 | – | Form 10-Q (filed 2018-08-06) ↗ |
Breakdown
What makes up total product sales ($m)
- Total product sales excluding Veklury (Base business, $M)7,604 · Q2 2026
- Total product sales — U.S. ($M)5,601 · Q2 2026
- Total product sales — Europe ($M)1,155 · Q2 2026
- Total product sales — Rest of World ($M)872 · Q2 2026
- Total product sales YoY growth (%)8.0% · Q2 2026
- Share of product sales denominated in foreign currencies (%)–
Cite this data
StockData. (2026). Gilead Sciences Total product sales ($M) ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rev_product_sales
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.